Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Lupin Ltd (LUPIN) is currently trading at 2,281.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Lupin is a global, innovation-led pharmaceutical company that develops and markets branded and generic formulations, biosimilars, injectables, inhalation products and APIs across 100+ countries, with particular strength in cardiovascular, diabetology, respiratory and anti-TB. The company combines a large India commercial footprint with a growing regulated-market presence in the United States and other developed markets. Q3 FY26 was a company record: consolidated sales of INR 71,005 million (↑26% YoY), EBITDA of INR 22,095 million (↑62% YoY) with a 31.1% margin, and net income of INR 11,756 million (↑38% YoY); Lupin highlighted broad-based regional growth led by a USD 350 million quarter in the US, driven by Tolvaptan, Mirabegron and new product momentum. Lupin is pivoting R&D and commercial strategy toward complex generics, injectables and biosimilars: the company announced US FDA approval for pegfilgrastim (Armlupeg™), has a rich pipeline of inhalation, injectables and biosimilars targeting multiple launches through FY28–FY31, and plans 10–15 ANDA filings in FY26 while targeting 100+ new product launches across platforms by FY31. India remains a core growth engine with the Rx business growing 10.9% in Q3 FY26 and chronic therapies now ~67% of the portfolio; Lupin is building a semaglutide-focused division, expects to be a day-one participant in obesity/GLP-1 launches, and projects sustained outperformance of the domestic market through product launches and salesforce expansion. Lupin is strengthening its ESG credentials while scaling complex product capability: the company achieved a 91/100 S&P Global ESG rating, CDP double A, SBTi approval for GHG targets and is advancing water recycling and zero-waste initiatives, underlining a simultaneous focus on sustainability, regulatory compliance improvements and quality remediation across manufacturing sites.
Over the past 52 weeks, Lupin Ltd has traded between a low of ₹1,838.65 and a high of ₹2,376.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Lupin Ltd has a market capitalization of approximately 1,04,400.67. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Lupin Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.58 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,04,400.67 Cr, Lupin Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Lupin Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Lupin Ltd is 19.58. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Lupin launched Mirabegron Extended-Release Tablets, 50 mg in the United States after receiving US FDA approval.
Lupin disclosed tentative approvals for Sugammadex Injection (March 31, 2026) and Pitolisant Tablets (March 25, 2026) through separate ANDA filings.
Lupin said it entered into a non-exclusive patent licence agreement with Takeda to commercialise Vonoprazan tablets in India.
Nuvama said there is limited upside left after the recent uptick and flagged growing product concentration risk, even though Q4 FY26 profitability and margins were strong.
Secretarial Compliance
Lupin Limited submitted its Secretarial Compliance Report for the financial year ended March 31, 2026, issued by Makarand M. Joshi & Co., pursuant to SEBI LODR Regulation 24A.
ESG Index Inclusion
Lupin announced its first‑time inclusion in the Dow Jones Best‑in‑Class World and Emerging Markets Indices, citing strong S&P Global CSA ESG performance (91/100) and enhanced sustainability credentials.
ESG Index Inclusion
Lupin announced first-time inclusion in the Dow Jones Best‑in‑Class World and Emerging Markets indices, reflecting top ESG performance (S&P Global CSA 2025 score 91/100) and recognition as a sustainability leader.
Regulatory Approval
Lupin announced U.S. FDA tentative approval for its ANDA for Revefenacin Inhalation Solution (175 mcg/3 mL unit-dose), bioequivalent to Mylan’s Yupelri®, which had ~USD 260.7M estimated U.S. annual sales.
Tentative Approval
Lupin received U.S. FDA tentative approval for its ANDA for Revefenacin Inhalation Solution 175 mcg/3 mL unit-dose vials, bioequivalent to Yupelri® for COPD; the reference drug had estimated U.S. sales of USD 260.7M (IQVIA Mar 2026).
Earnings Transcript
Transcript of Q4 FY26 results: Q4 revenue Rs 7,475 Cr (+32% YoY) and EBITDA Rs 2,171 Cr (+68% YoY); FY26 revenue Rs 27,958 Cr (+23%) and FY EBITDA Rs 8,160 Cr (+55%); US sales USD 1.318bn (+40%); FY27 guidance: high-single-digit growth, ~25% margins.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1361.00 | 1,13,052 Cr | 29.14 | 3.28 | 0.93 | 11.27 | 14.95 | 9.11 | ||
1307.00 | 1,10,333 Cr | 26.29 | 2.91 | 0.61 | 11.07 | 12.54 | 7.15 | ||
2507.00 | 1,06,669 Cr | 55.76 | 6.54 | 0.00 | 11.74 | 13.13 | 6.90 | ||
864.25 | 1,04,744 Cr | 20.78 | 3.86 | 0.10 | 18.59 | 17.35 | 9.59 | ||
2326.80 | 1,04,401 Cr | 19.58 | 4.65 | 0.79 | 23.76 | 24.88 | 13.96 | ||
1415.00 | 88,160 Cr | 25.28 | 2.52 | 0.00 | 9.77 | 12.69 | 6.63 | ||
1129.60 | 73,491 Cr | 82.69 | 13.87 | 0.09 | 16.77 | 16.14 | 8.47 | ||
| Median: 7 Co. | — | 1361.00 | 1,04,744 Cr | 26.29 | 3.86 | 0.10 | 11.74 | 14.95 | 8.47 |
Bearish
3
Neutral
7
Bullish
4
Bearish
20
Neutral
7
Bullish
19
Bearish
17
Neutral
0
Bullish
15
Lupin is a global, innovation-led pharmaceutical company that develops and markets branded and generic formulations, biosimilars, injectables, inhalation products and APIs across 100+ countries, with particular strength in cardiovascular, diabetology, respiratory and anti-TB. The company combines a large India commercial footprint with a growing regulated-market presence in the United States and other developed markets.
Q3 FY26 was a company record: consolidated sales of INR 71,005 million (↑26% YoY), EBITDA of INR 22,095 million (↑62% YoY) with a 31.1% margin, and net income of INR 11,756 million (↑38% YoY); Lupin highlighted broad-based regional growth led by a USD 350 million quarter in the US, driven by Tolvaptan, Mirabegron and new product momentum.
Lupin is pivoting R&D and commercial strategy toward complex generics, injectables and biosimilars: the company announced US FDA approval for pegfilgrastim (Armlupeg™), has a rich pipeline of inhalation, injectables and biosimilars targeting multiple launches through FY28–FY31, and plans 10–15 ANDA filings in FY26 while targeting 100+ new product launches across platforms by FY31.
India remains a core growth engine with the Rx business growing 10.9% in Q3 FY26 and chronic therapies now ~67% of the portfolio; Lupin is building a semaglutide-focused division, expects to be a day-one participant in obesity/GLP-1 launches, and projects sustained outperformance of the domestic market through product launches and salesforce expansion.
Lupin is strengthening its ESG credentials while scaling complex product capability: the company achieved a 91/100 S&P Global ESG rating, CDP double A, SBTi approval for GHG targets and is advancing water recycling and zero-waste initiatives, underlining a simultaneous focus on sustainability, regulatory compliance improvements and quality remediation across manufacturing sites.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,04,291 Cr
Low Risk
19.6
34.8
0.3
4.7
2,376.00
1,838.65
Sales CAGR
Profit CAGR
ROE
ROCE
